Connect your AI

GeneDx Holdings WGS Stock-Based Comp

Stock-Based Comp at other companies

Natera, Inc.NTRA

$95.11M+22.2%

Tempus AI, Inc.TEM

$52.71M+129%

Quest DiagnosticsDGX

$20M-9.1%

RevvityRVTY

$8.72M+12.7%

Labcorp HoldingsLH

$31.7M-3.4%

IlluminaILMN

$60M-17.8%

Other financials

Income statement

Revenue$102.3M+17.4%

Gross profit$68.2M+16.6%

Operating income-$57.5M-1,163%

Net income-$63.3M-870%

EPS (diluted)-$2.16-839%

Balance sheet

Cash & equivalents$94.9M-5.7%

Total debt$96.7M+82.5%

Total equity$254.1M-1.3%

Total assets$506.3M+13.4%

Cash flow

Operating cash flow-$32.4M-418%

CapEx$6.5M+5.3%

Free cash flow-$38.9M-1,059%

Valuation

Market cap$1.72B-24.3%

Enterprise value$1.73B-22.8%

P/S3.9×-3.0×

Profitability

Gross margin69.6%+4.3pp

Operating margin-14.9%—

Net margin-17.6%—

FCF margin3.8%+2.1pp

Returns & leverage

Return on equity-30.4%—

Debt / equity0.4×+0.2×

Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is GeneDx Holdings's stock-based comp?: GeneDx Holdings (WGS) reported stock-based comp of $9M in Q1 2026.
How has GeneDx Holdings's stock-based comp changed year-over-year?: GeneDx Holdings's stock-based comp increased by 125.9% year-over-year, from $3.98M to $9M.
What is the long-term trend for GeneDx Holdings's stock-based comp?: Over 4 years (2021 to 2025), GeneDx Holdings's stock-based comp has grown at a -38.2% compound annual growth rate (CAGR), from $219.94M to $32.16M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.